I've said for years that "Alzheimer's" is actually a cluster of different diseases, and that's why some drugs show great results for a percentage of patients but do nothing for others -- so their clinical trials fail. The former head of Vertex just joined the board of a very small biotech and that's what HE thinks. The small company just did a Phase II.

Quote:

---

Boger said too many drugmakers “barrel through” Phase II testing, instead of using those studies to explore a molecule’s best path forward. An after-the-fact data cut showed the drug appeared to be particularly effective in patients with dementia with Lewy bodies, or DLB, who didn’t show certain signs of Alzheimer’s disease. CervoMed’s next study is only recruiting this group of patients,, or “pure DLB” patients. The company expects topline results from the placebo-controlled study in the second half of 2024.

---

https://endpts.com/vertex-founder-joshua-boge...g-readout/